

Photochemical & Photobiological Sciences

Accepted Manuscript




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Graphical abstract



Wavelength-dependent forward ($\Phi_{A \rightarrow B}^{\lambda_{irr}}$) and reverse ($\Phi_{B \rightarrow A}^{\lambda_{irr}}$) *Fluvo* quantum yields.

1 **Quantitative assessment of photostability and**
2 **photostabilisation of Fluvoxamine**
3 **and its design for actinometry.**

4
5
6 Mounir Maafi*, Wassila Maafi

7
8
9 *Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH,*
10 *UK*

11
12
13
14 *Corresponding Author: e-mail: mmaafi@dmu.ac.uk (m maafi);
15
16

17

18

19

20

21 **Abstract**

22 Despite the numerous concerns that have been raised in relation to considering 0th, 1st and
23 2nd-order kinetic treatments for drugs' photodegradation characterisation and assessments,
24 yet they still are employed, as the only tool available for these types of studies. The recently
25 developed Φ -order kinetic models have opened new perspectives in the treatment of
26 photoreaction kinetics that stands as the best known alternative to the classical approach.
27 The Φ -order kinetics have been applied here to Fluvoxamine (Fluvo) with the aim to set out
28 a detailed and comprehensive procedure able to rationalise
29 photodegradation/photostability of drugs and propose a platform for photosafety studies.
30 Our results prove that drugs' quantum yields ($0.0016 <$
31 $\Phi_{Fluvo}^{\lambda_{irr}} < 0.43$) should *a priori* be considered wavelength-dependent, their
32 photostabilisation (up to 75% for Fluvo) by means of absorption competitors could explicitly
33 be related to a decrease of the photokinetic factor, and photoreversible drugs can be
34 developed into efficient actinometers (as Fluvoxamine in the 260–290 nm range). A pseudo-
35 rate-constant factor was proposed as a descriptive parameter, circumventing the
36 limitations of overall rate-constants and allowing comparison between drugs' kinetic data
37 obtained in different conditions.

38

39 **Keywords:**

40 Photodegradation, photokinetics, Fluvoxamine, actinometry, photosafety, photostabilization.


41

42 1. INTRODUCTION

43 A vast number of drugs have been shown to be adversely affected by light both *in vivo* and *in*
44 *vitro*.¹⁻⁴ Consequently, several studies have been devoted to the elucidation of the
45 mechanisms, photo-products, kinetics and photoprotection strategies of such
46 photodegradation reactions.⁵⁻⁷ Thus far, the kinetic analysis of these reactions has relied
47 solely on the classical thermal zeroth-, first- and second-order reaction models.^{5,6}
48 Nevertheless, despite the fact that it soon became evident that such treatment strategies are
49 not suited for photochemical reactions, they continued to be employed, mainly due to the lack
50 of more adequate alternative treatments, procedures and methods. This situation has
51 considerably limited the scope and reliability of drugs' photodegradation and
52 photostabilisation studies. The efforts that may have been devoted to proposing integrated
53 rate-laws for photokinetic data that truly reflect the evolution of photoreactions are very
54 scarce in the literature and predominantly based on approximations. This *status quo* is due to
55 the tedious and mostly unsolvable mathematical hurdles encountered during integration of
56 photoreactions' differential equations.^{8,9} Recently, an approach was proposed whereby semi-
57 empirical rate-law model equations could be developed for photodegradation reactions. It has
58 also been shown that such photoreactions obeyed a Φ -order kinetics, with a quite different
59 formulation to the classical ones.^{10,11} The Φ -order kinetic models, which proved to
60 successfully describe drugs' photoreactions undergoing unimolecular or reversible
61 isomerization,^{10,12} have considerably facilitated photostability investigations.

62 *Fluvo* is a selective serotonin (5-hydroxytryptamine, 5-HT) neuronal re-uptake
63 inhibitor (SSRI) used in the treatment of depression and anxiety.¹³⁻¹⁵ It has a few side effects¹⁶
64 and little or no anticholinergic effect which makes it a much less hazardous drug than other
65 antidepressants especially in overdose quantities.^{17,18}

66 While this molecule is stable to hydrolysis,¹⁹ it undergoes reversible geometric
 67 photoisomerism under UV irradiation around the oxime linker group, Scheme 1.²⁰ The
 68 occurrence of only one photoproduct (*Z-Fluvo*) was evidenced for the photodegradation of
 69 *E-Fluvo*.^{20,21} While a number of pharmacological experiments have failed to link the *Z*-
 70 isomer to any phototoxicity, it was nonetheless found to be a 150-times less potent than its
 71 *E*-counterpart when tested on cortical synaptosomes.^{19,22} UVB irradiation was deemed
 72 responsible for *E-Fluvo* isomerisation and thus interaction of this type of radiation with
 73 *Fluvo* and subsequent isomerisation could occur even *in vivo* since UVB is able to reach
 74 blood vessels in the dermis.²⁰ Incidentally, the occurrence of SSRIs in aquatic environments,
 75 wastewater and even drinking water sources has also been reported.²³ As such, the study of
 76 the photodegradation kinetics of these drugs becomes important not only from a
 77 pharmacological but also from an environmental point of view.



78 **Scheme 1:** *E/Z* (Anti/Syn) reversible photoisomerism of *Fluvo*
 79 upon exposure to UV-irradiation.
 80

81
 82 Very little is known on the photodegradation kinetics of *Fluvo*.^{20,21} Its
 83 photodegradation was attributed the pseudo-first order kinetics under fluorescent lamp
 84 irradiation (with a beam's bandwidth of 110 nm, ranging between 290–400 nm with a
 85 maximum emission at 312 nm)²¹ and differing half-life times were recorded depending on
 86 the spectral output of the lamps used for irradiation.²⁰ Relatively low quantum yield values of
 87 *Fluvo* photodegradation in different aqueous media (1.87×10^{-3} to 8.55×10^{-3}) have been

88 recorded for the experiment using irradiation light from fluorescent lamps.²¹ Nevertheless, to
89 the best of our knowledge, neither quantum yield determination for the individual forward (E
90 $\rightarrow Z$) and reverse ($Z \rightarrow E$) reactions nor experiments involving UVB radiation have, thus far,
91 been attempted.

92 In this paper, the issues highlighted above have been addressed together with a
93 quantification of the effect of light absorbing competitors and *Fluvo* suitability for
94 actinometry.

95 2. Materials and methods

96 2.a Materials

97 Fluvoxamine maleate, 2-[[*E*]-{5-Methoxy-1-[4-(trifluoromethyl)phenyl] pentylidene}
98 amino]oxy}ethanamine (*E-Fluvo*), glacial acetic acid and Spectrophotometric grade
99 acetonitrile were purchased from Sigma-Aldrich. Double distilled water was used as the
100 solvent.

101

102 2.b Monochromatic continuous irradiation

103 For irradiation experiments, a Ushio 1000 W xenon arc-lamp light source housed in a
104 housing shell model A6000 and powered by a power supply model LPS-1200, was used.
105 This setting was cooled by tap water circulation through a pipe system. The lamp housing
106 was connected to a monochromator model 101 that allows the selection of specific irradiation
107 wavelengths since it consists of a special *f*/2.5 monochromator with a 1200 groove/mm at
108 300 nm blaze grating. The excitation beam was guided through an optical fibre to impinge
109 from the top of the sample cuvette i.e. the excitation and the analysis light beams were
110 perpendicular to each other. The set up (lamp, lamp housing and monochromator) was
111 manufactured by Photon Technology International Corporation.

112

113 2.c The monitoring system

114 A diode array spectrophotometer (Agilent 8453) was used to measure the various absorption
115 spectra and kinetic profiles for the irradiation and calibration experiments. This
116 spectrophotometer was equipped with a 1-cm cuvette sample holder and a Peltier system
117 model Agilent 8453 for temperature control. As such, the sample was kept at 22°C, stirred

118 continuously during the experiment, and completely shielded from ambient light. The
119 spectrophotometer was monitored by an Agilent 8453 Chemstation kinetics–software.

120 A Radiant Power/Energy meter model 70260 was used to measure the radiant power
121 of the incident excitation beams.

122

123 **2.d Kinetic data treatment**

124 In order to carry out non–linear fittings and to determine best–fit curves, a Levenberg–
125 Marquardt iterative program within the Origin 6.0 software was used.

126

127 **2.e HPLC measurements**

128 The HPLC system consisted of a reversed–phase Jupiter 5 μ C–18 300A Phenomenex (250 x
129 4.60 mm) column equipped with Perkin Elmer Series 200 pump, UV/Vis detector, vacuum
130 degasser and a Perkin Elmer type Chromatography Interface 600 series Link linked to a
131 computer system.

132 The mobile phase consisted of 60 % double distilled water adjusted to pH 4.8 with
133 glacial acetic acid and 40 % acetonitrile. A flow rate of 1.5 ml/min and an injection loop of
134 20 μ l were used. The detector wavelength was set at 245 nm. Retention times of 10 and 8.32
135 min were recorded for E and Z isomers, respectively.

136

137 **2.f Fluvo solutions**

138 A 2.88×10^{-4} M stock solution of *Fluvo* in water was prepared by weighing the solid. The
139 flask was protected from light by aluminium foil wrapping and was kept in the fridge. The

140 stock solution was diluted to prepare fresh analytical solutions (*ca.* 2×10^{-6} M) for analysis of
141 irradiation experiments performed at various wavelengths.

142 For actinometric studies, *Fluvo* solutions of the same concentrations (*ca.* 2.9×10^{-6}
143 M) were exposed to specific wavelengths irradiations (260, 270, 280, 285 and 290 nm) using
144 a series of different intensities for each wavelength. The kinetic traces were observed at the
145 observation wavelength $\lambda_{obs} = 245$ nm and subsequently fitted with the Φ -order equations.

146 Experiments were conducted at least in triplicates.

147

148

149 3. RESULTS AND DISCUSSION

150 3.a The Mathematical background

151 3.a.1 Φ -Order kinetics for non-isosbestic irradiation

152 The kinetic data of direct unimolecular photoreactions and photoreversible dimolecular
153 phototransformations, collected at non-isosbestic and monochromatic irradiation at constant
154 temperature, have recently been shown to obey Φ -order kinetics.^{8,10-12} Φ -order kinetics is
155 much more suitable to describe photoreactions than the classical treatments proposed for
156 zeroth-, first- and second-order thermal reactions. Even though ubiquitous, the treatment of
157 photokinetics on the basis of the latter classical reaction orders is unreliable, for at least three
158 main drawbacks inherently linked to this approach. Firstly, the differential equations of
159 photoreactions are generally different from and not possibly integrated in closed-forms as is
160 the case for thermal reactions of 0th-, 1st-or 2nd- order. This means that using such classical
161 orders' treatments for the quantitative investigation of photoreactions must be considered as a
162 mere approximation. Secondly, literature data have reported that the classical approach may
163 lead to a confusion about the reaction order that should be attributed to the photodegradation
164 reaction at hand given that the kinetic data of a given reaction (generally up to half-life time)
165 can well be fitted by the equations corresponding to two different reaction orders (most
166 commonly 0th- and 1st-order). Thirdly, the rate-constant values determined from the
167 experimental data of photodegradation cannot be analytically linked to the experimental
168 conditions and/or reaction attributes. This has made it difficult to compare such rate constants
169 between compounds and/or laboratories.

170 In this context, the approach adopted to develop the equations of Φ -order kinetics
171 offers a more robust mathematical framework to investigate photoreactions. The model
172 equation, a logarithmic expression involving a time-dependent exponential term, for

173 unimolecular photoreactions where only the initial species absorbs, have been derived
174 through closed-form integration.⁸ This model equation has represented the basis to develop
175 the semi-empirical model equations for both the unimolecular photoreaction where both
176 initial species and photoproduct absorb, and photoreversible reactions. They have been
177 optimised by studying simulated photoreaction traces obtained by numerical Runge-Kutta
178 integration methods.^{10,11} These traces, calculated for a wide range of experimental conditions
179 for unimolecular¹⁰ and reversible photoreactions,¹¹ served for referencing the reliability and
180 validation of the proposed semi-empirical integrated rate-laws.

181 A unique set of general equations (Eqs. 1a,b) can be derived for photochemical
182 reactions involving two species, the initial molecule, A, and its photoproduct, B, whose
183 transformations might be achieved by one ($A \rightarrow B$) or two ($A \rightleftharpoons B$) photochemical steps,
184 each one characterised by a specific photoreaction quantum yield (Φ_{AB} and Φ_{BA}). Such
185 systems are labelled as AB(1 Φ) and AB(2 Φ), respectively. Hence, if assumed that the
186 concentration of the excited state is negligible during the progress of the photoreaction while
187 the reaction medium is concomitantly maintained at a constant temperature, homogeneously
188 stirred, and continuously irradiated with a monochromatic beam (with the latter beam's non-
189 isosbestic wavelength (λ_{irr}) correspond to a spectral region where species A and B absorb
190 different amounts of light (P), i.e., the absorption coefficients (ϵ) of the species are different
191 and might have non-zero values ($\epsilon_A^{\lambda_{irr}} \neq \epsilon_B^{\lambda_{irr}} \neq 0$)), then in these conditions, the
192 concentration profiles, $C_A(t)$ and $C_B(t)$, are dependent on the species absorption
193 coefficients, and given by

194

$$C_A(t) = C_A(\infty) + \frac{\text{Log} \left[1 + \left(10 \left[\left(\varepsilon_A^{\lambda_{irr}} - \varepsilon_B^{\lambda_{irr}} \right) \times (C_A(0) - C_A(\infty)) \times l_{\lambda_{irr}} \right] - 1 \right) \times e^{-k_{A \rightleftharpoons B}^{\lambda_{irr}} \times t} \right]}{\left(\varepsilon_A^{\lambda_{irr}} - \varepsilon_B^{\lambda_{irr}} \right) \times l_{\lambda_{irr}}} \quad (1a)$$

195

$$C_B(t) = C_B(\infty) \times \left(1 - \frac{\text{Log} \left[1 + \left(10 \left[\left(\varepsilon_A^{\lambda_{irr}} - \varepsilon_B^{\lambda_{irr}} \right) \times (C_A(0) - C_A(\infty)) \times l_{\lambda_{irr}} \right] - 1 \right) \times e^{-k_{A \rightleftharpoons B}^{\lambda_{irr}} \times t} \right]}{\left(\varepsilon_A^{\lambda_{irr}} - \varepsilon_B^{\lambda_{irr}} \right) \times (C_A(0) - C_A(\infty)) \times l_{\lambda_{irr}}} \right) \quad (1b)$$

196 were $k_{A \rightleftharpoons B}^{\lambda_{irr}}$ is the overall reaction rate-constant, and $l_{\lambda_{irr}}$ is the optical path length of the
 197 excitation light across the reactive medium.

198 For spectrophotometric monitoring of the reaction's evolution, it is preferable to use
 199 the logarithmic integrated rate-law equation describing the variation of the total observed
 200 absorption ($A_{tot}^{\lambda_{irr}/\lambda_{obs}}(t)$) with time:¹¹

201

$$A_{tot}^{\lambda_{irr}/\lambda_{obs}}(t) = A_{tot}^{\lambda_{irr}/\lambda_{obs}}(\infty) + \frac{A_A^{\lambda_{irr}/\lambda_{obs}}(0) - A_{tot}^{\lambda_{irr}/\lambda_{obs}}(\infty)}{A_A^{\lambda_{irr}/\lambda_{irr}}(0) - A_{tot}^{\lambda_{irr}/\lambda_{irr}}(\infty)} \times \frac{l_{\lambda_{obs}}}{l_{\lambda_{irr}}} \text{Log} \left[1 + \left(10 \left[\left(A_A^{\lambda_{irr}/\lambda_{irr}}(0) - A_{tot}^{\lambda_{irr}/\lambda_{irr}}(\infty) \right) \times \frac{l_{\lambda_{irr}}}{l_{\lambda_{obs}}} \right] - 1 \right) \times e^{-k_{A \rightleftharpoons B}^{\lambda_{irr}} \times t} \right] \quad (2)$$

202

203 Eq.2 involves only the cumulative observed absorbances ($A_{tot}^{\lambda_{irr}/\lambda_{obs}}$) of the medium
 204 which have been measured under the observation ($l_{\lambda_{obs}}$) and not the excitation ($l_{\lambda_{irr}}$)
 205 condition (with $l_{\lambda_{obs}}$ being the optical path length of the monitoring light inside the sample).
 206 These optical path lengths ($l_{\lambda_{irr}}$ and $l_{\lambda_{obs}}$) are not necessarily equal for a given experiment,

207 and the absorbance of the medium in the excitation conditions (i.e. corresponding to a
 208 measurement along $l_{\lambda_{irr}}$) may not be directly accessible during the experiment.

209 The coefficients $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(t)$, $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(0)$, $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(pss)$, $A_{tot}^{\lambda_{irr}/\lambda_{irr}}(0)$ and
 210 $A_{tot}^{\lambda_{irr}/\lambda_{irr}}(pss)$ in Eq.2 are the measured (along $l_{\lambda_{obs}}$) total absorbances of the medium
 211 respectively recorded at reaction time t , at the initial time ($t = 0$) and either at the end of the
 212 reaction or at the photostationary state (pss , where $t = \infty$). The reaction medium is irradiated
 213 at a given irradiation wavelength and simultaneously monitored at either a different
 214 observation wavelength ($\lambda_{irr}/\lambda_{obs}$) or at the same wavelength ($\lambda_{irr}/\lambda_{irr}$). It is assumed that
 215 the reaction is quantitative and proceeds without by-products.

216 The analytical expression of the exponential factor, $k_{A \rightleftharpoons B}^{\lambda_{irr}}$, in Eqs.1 and 2 which
 217 represents the overall reaction rate-constant, is given by,¹¹

218

$$219 \quad k_{A \rightleftharpoons B}^{\lambda_{irr}} = \left(\Phi_{A \rightarrow B}^{\lambda_{irr}} \times \varepsilon_A^{\lambda_{irr}} + \Phi_{B \rightarrow A}^{\lambda_{irr}} \times \varepsilon_B^{\lambda_{irr}} \right) \times l_{\lambda_{irr}} \times F_{\lambda_{irr}}(\infty) \times P_{\lambda_{irr}} = \beta_{\lambda_{irr}} \times P_{\lambda_{irr}} \quad (3)$$

220

221 where $\Phi_{A \rightarrow B}^{\lambda_{irr}}$ and $\Phi_{B \rightarrow A}^{\lambda_{irr}}$ are the forward and reverse quantum yields of the reaction
 222 photochemical steps realised at the irradiation wavelength (λ_{irr}); $P_{\lambda_{irr}}$ is the radiant power
 223 (expressed in einstein $\text{dm}^{-3} \text{s}^{-1}$); $\beta_{\lambda_{irr}}$ is a proportionality factor, and $F_{\lambda_{irr}}(\infty)$ the time-
 224 independent photokinetic factor expressed as:

225

$$F_{\lambda_{irr}}(\infty) = \frac{1 - 10^{-\left(A_{tot}^{\lambda_{irr}/\lambda_{irr}(\infty)} \times \frac{l_{\lambda_{irr}}}{l_{\lambda_{obs}}}\right)}}{A_{tot}^{\lambda_{irr}/\lambda_{irr}(\infty)} \times \frac{l_{\lambda_{irr}}}{l_{\lambda_{obs}}}} \quad (4)$$

226 As it has been previously shown,¹¹ Eq.2 describing the kinetics of AB(2Φ) systems,
 227 can also allow retrieving the equations set out for pure unimolecular AB(1Φ) reactions
 228 ($\Phi_{B \rightarrow A}^{\lambda_{irr}} = 0$), where either (i) only the initial compound absorbs the irradiation light (in these
 229 conditions $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(\infty) = 0$ and $F_{\lambda_{irr}}(\infty) = 2.3 \cong \ln(10)$)^{8,24} or (ii) both the initial
 230 compound and its photoproduct (A and B) absorb light at the irradiation wavelength (which
 231 corresponds to complete depletion of species A, and therefore, $F_{\lambda_{irr}}(\infty)$ is calculated using
 232 Eq.3 with $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(\infty) = A_B^{\lambda_{irr}/\lambda_{obs}}(\infty) = \varepsilon_B^{\lambda_{irr}} \times l_{\lambda_{irr}} \times C_A(0)$).¹⁰

233 The differentiation of Eq.2 yields the expression of the initial velocity of the reaction
 234 $\left(\left(\frac{dA_{tot}}{dt}\right)_{t=0} = v_0^{\lambda_{irr}/\lambda_{obs}(\text{mod.})}\right)$, for the kinetic trace involving the variation of the total
 235 absorbance,¹¹

$$v_0^{\lambda_{irr}/\lambda_{obs}(\text{mod.})} = \left(\frac{dA_{tot}^{\lambda_{irr}/\lambda_{obs}}}{dt}\right)_0$$

$$= \frac{A_{tot}^{\lambda_{irr}/\lambda_{obs}}(0) - A_{tot}^{\lambda_{irr}/\lambda_{obs}}(pss)}{A_{tot}^{\lambda_{irr}/\lambda_{irr}}(0) - A_{tot}^{\lambda_{irr}/\lambda_{irr}}(pss)} \times \frac{k_{A \rightleftharpoons B}^{\lambda_{irr}(\text{mod.})}}{\frac{l_{\lambda_{irr}}}{l_{\lambda_{obs}}} \times \ln(10)}$$

$$\times \left(10^{\left(A_{tot}^{\lambda_{irr}/\lambda_{irr}}(pss) - A_{tot}^{\lambda_{irr}/\lambda_{irr}}(0)\right) \times \frac{l_{\lambda_{irr}}}{l_{\lambda_{obs}}} - 1}\right) \quad (5)$$

236 The numerical value of Eq.5, obtained graphically, corresponds to the theoretical
 237 expression derived from the differentiation of the reaction,¹¹ as

$$\begin{aligned}
 v_{0(cld.)}^{\lambda_{irr}/\lambda_{obs}} &= \left(\varepsilon_B^{\lambda_{obs}} - \varepsilon_A^{\lambda_{obs}} \right) \times l_{\lambda_{obs}} \times \Phi_{A \rightarrow B}^{\lambda_{irr}} \times \varepsilon_A^{\lambda_{irr}} \times l_{\lambda_{irr}} \times F_{\lambda_{irr}}(0) \times C_0 \times P_{\lambda_{irr}} \\
 &= \delta_{\lambda_{irr}} \times P_{\lambda_{irr}}
 \end{aligned} \tag{6}$$

238

239 When calculating $v_{0(cld.)}^{\lambda_{irr}/\lambda_{obs}}$, the photokinetic factor $F_{\lambda_{irr}}(t)$ at time $t = 0$ takes the value of

240 $F_{\lambda_{irr}}(0)$, that is determined using $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(0) = \varepsilon_A^{\lambda_{irr}} \times l_{\lambda_{irr}} \times C_A(0)$ in lieu of

241 $A_{tot}^{\lambda_{irr}/\lambda_{obs}}(\infty)$ in Eq.4. $\delta_{\lambda_{irr}}$ is a proportionality factor.

242 Because Eqs.1 and 2 are semi-empirical, their application has been limited to

243 $F_{\lambda_{irr}}(\infty)$ values higher than 1.2. This condition is easily met by reducing the values of either

244 the initial concentration of species A or the optical path length for irradiation, $l_{\lambda_{irr}}$.^{10,11}

245

246 3.a.2 Isosbestic irradiations equations

247 In the case where the monochromatic irradiation of the solution is realised at an isosbestic

248 point, $\lambda_{irr} = \lambda_{isos}$ (only a few isosbestic points are usually present on the electronic spectra

249 of AB(2 Φ) reactions), the general integrated rate-law of AB reaction systems has been

250 obtained through a closed-form integration,²⁵ as

$$251 \quad C_A(t) = C_A(\infty) + (C_A(0) - C_A(\infty)) \times e^{-k_{A \rightleftharpoons B}^{\lambda_{isos}} \times t} \tag{7}$$

$$C_B(t) = C_B(\infty) - C_B(\infty) \times e^{-k_{A \rightleftharpoons B}^{\lambda_{isos}} \times t} \tag{8}$$

252

253 with $C_A(\infty)$ and $C_B(\infty)$, the concentrations of the species at either the end of the reaction or
 254 pss ($t = \infty$) and $k_{A \rightleftharpoons B}^{\lambda_{isos}}$, the overall rate-constant of the reaction performed at an isosbetic
 255 irradiation.

256 $k_{A \rightleftharpoons B}^{\lambda_{isos}}$ has the same analytical expression as Eq.3 but with λ_{isos} replacing λ_{irr} and
 257 the photokinetic factor $F_{\lambda_{isos}}$ used instead of $F_{\lambda_{irr}}(\infty)$. $F_{\lambda_{isos}}$ is calculated using Eq.4 with
 258 $A_{tot}^{\lambda_{isos}/\lambda_{isos}}$ instead of $A_{tot}^{\lambda_{irr}/\lambda_{irr}}(\infty)$.

259 The value of the initial velocity can be obtained graphically and compared to its
 260 theoretical expression (Eq.9).

261

$$v_0^{\lambda_{isos}/\lambda_{isos}} = -k_{A \rightleftharpoons B}^{\lambda_{isos}} \times (C_A(0) - C_A(pss)) = -\Phi_{A \rightarrow B}^{\lambda_{isos}} \times C_A(0) \times \varepsilon_A^{\lambda_{isos}} \times l_{\lambda_{isos}} \times P_{\lambda_{isos}} \times F_{\lambda_{isos}} \quad (9)$$

262

263 The monoexponential form of the equations 7 and 8 indicates that isosbestic
 264 irradiations induce first-order kinetics for AB(2 Φ) reactions. This is primarily due to the fact
 265 that when $\lambda_{irr} = \lambda_{isos}$, the photokinetic factor does not vary with reaction time (as the
 266 medium absorbance at the irradiation wavelength, λ_{isos} , is time-independent).

267

268 3.a.3 The kinetic elucidation method for AB(2 Φ) photoreversible reactions

269 If, a priori, we suppose that the quantum yields of the photoreaction are wavelength-
 270 dependent (until proven otherwise) and the spectra of the species A and B overlap, then the
 271 equations set out above for both isosbetic (Eqs.7 and 8) and non-isosbestic (Eq.1 and 2)
 272 irradiations can fit well the AB(2 Φ) experimental traces obtained photometrically, however,

273 the extracted fitting parameters ($k_{A\rightleftharpoons B}^{\lambda_{isos}}$ and $v_0^{\lambda_{isos}/\lambda_{obs}}$ or $k_{A\rightleftharpoons B}^{\lambda_{irr}}$ and $v_0^{\lambda_{irr}/\lambda_{obs}}$), which
 274 represent two equations for each irradiation condition, are not sufficient to work out the three
 275 unknowns of the reaction namely, its photochemical quantum yield values and the absorption
 276 coefficient, $\varepsilon_B^{\lambda_{irr}}$, (i.e. the electronic spectrum) of the photoproduct, if none of the latter is
 277 available prior to the experiment. Solving the kinetics by using only the fitting parameters
 278 (irrespective of the number of $\lambda_{irr}/\lambda_{obs}$ traces) leads to a degenerate kinetic solution with
 279 inextricable identifiability and/or distinguishability issues.²⁶

280 In order to overcome this situation, we have recently proposed a simple elucidation
 281 method for photoreversible reactions that can be implemented in three steps.²⁶

282 Firstly, the reaction quantum yields are determined for an isosbestic irradiation. The
 283 variation of the species concentrations during photodegradation, under a monochromatic
 284 irradiation at an isosbestic point, is monitored by HPLC. At the given irradiation wavelength
 285 (λ_{isos}), the absorption coefficient of the photoproduct is known ($\varepsilon_A^{\lambda_{isos}} = \varepsilon_B^{\lambda_{isos}}$) and
 286 therefore, the number of unknowns is only two ($\Phi_{A\rightarrow B}^{\lambda_{isos}}$ and $\Phi_{B\rightarrow A}^{\lambda_{isos}}$) for this experiment.

287 Hence, fitting the experimental data with Eqs.7 and 8 provides the numerical values
 288 for the reaction initial velocity ($v_0^{\lambda_{isos}}$, Eq. 9) and the reaction overall rate-constant ($k_{A\rightleftharpoons B}^{\lambda_{isos}}$). In
 289 these conditions, solving the system of two equations ($v_0^{\lambda_{isos}}$ and $k_{A\rightleftharpoons B}^{\lambda_{isos}}$), leads to the
 290 determination of the absolute values of $\Phi_{A\rightarrow B}^{\lambda_{isos}}$ (Eq.10) and $\Phi_{B\rightarrow A}^{\lambda_{isos}}$ (Eq.11), as

291

$$\Phi_{A\rightarrow B}^{\lambda_{isos}} = \frac{k_{A\rightleftharpoons B}^{\lambda_{isos}}}{\varepsilon_A^{\lambda_{isos}} \times l_{\lambda_{isos}} \times P_{\lambda_{isos}} \times F_{\lambda_{isos}}} \times \frac{(C_A(0) - C_A(pss))}{C_A(0)} \quad (10)$$

$$\Phi_{B \rightarrow A}^{\lambda_{isos}} = \frac{k_{A \rightleftharpoons B}^{\lambda_{isos}}}{\varepsilon_A^{\lambda_{isos}} \times l_{\lambda_{isos}} \times P_{\lambda_{isos}} \times F_{\lambda_{isos}}} - \Phi_{A \rightarrow B}^{\lambda_{isos}} \quad (11)$$

292

293 Both the species pss concentrations and the quantum yields' values, allow determining the
294 equilibrium constant (Eq.12),

295

$$K_{\rightleftharpoons}^{\lambda_{isos}} = \frac{k_{B \rightarrow A}^{\lambda_{isos}}}{k_{A \rightarrow B}^{\lambda_{isos}}} = \frac{C_B(pss)}{C_A(pss)} = \frac{\Phi_{A \rightarrow B}^{\lambda_{isos}}}{\Phi_{B \rightarrow A}^{\lambda_{isos}}} \quad (12)$$

296

297 It is worth noticing that $K_{\rightleftharpoons}^{\lambda_{isos}}$ is concentration-independent. This feature finds its
298 importance in the fact that the HPLC experiment that served its determination is usually
299 performed at initial concentrations of species A that are not suitable (too concentrated) for
300 spectrophotometric analyses (which are bound to be realised at lower concentration, specifically,
301 where $F_{\lambda_{irr}}(\infty) > 1.2$ as discussed above).

302 The reconstruction of the full spectrum of the photoisomer (B), can then be performed at
303 lower concentrations in the second step of the elucidation method. This is achieved from the value
304 of $K_{\rightleftharpoons}^{\lambda_{isos}}$ and the spectrum of the reactive medium recorded at *pss* under the same isosbestic
305 irradiation used for the HPLC experiment ($A_{tot}^{\lambda_{isos}/\lambda_{obs}}(pss)$), as

306

$$\varepsilon_B^{\lambda_{obs}} = \frac{(K_{\rightleftharpoons}^{\lambda_{isos}} + 1) \times A_{tot}^{\lambda_{isos}/\lambda_{obs}}(pss) - \varepsilon_A^{\lambda_{obs}} \times l_{obs} \times C_A(0)}{l_{obs} \times K_{\rightleftharpoons}^{\lambda_{isos}} \times C_A(0)} \quad (13)$$

308

309 Therefore, irrespective of the wavelength selected to perform the irradiation, the
 310 number of unknowns will constantly be two in total, as the spectrum of the photoproduct
 311 (ε_B^λ) is fully known.

312 Hence, in the last step of the method, the quantum yields for each non-isosbestic
 313 irradiation wavelength ($\Phi_{A \rightarrow B}^{\lambda_{irr}}$ and $\Phi_{B \rightarrow A}^{\lambda_{irr}}$) can readily be worked out by using Eq.6 and its
 314 numerical value given by Eq.5 (for $\Phi_{A \rightarrow B}^{\lambda_{irr}}$, Eq.14) and by rearranging Eq.3 (for $\Phi_{B \rightarrow A}^{\lambda_{irr}}$) to give
 315 Eq. 15.

316

$$\Phi_{A \rightarrow B}^{\lambda_{irr}} = \frac{U_0^{\lambda_{irr}/\lambda_{obs}}(mod.)}{(\varepsilon_B^{\lambda_{obs}} - \varepsilon_A^{\lambda_{obs}}) \times l_{\lambda_{obs}} \times \varepsilon_A^{\lambda_{irr}} \times l_{\lambda_{irr}} \times P_{\lambda_{irr}} \times F_0^{\lambda_{irr}} \times C_0} \quad (14)$$

317

$$\Phi_{B \rightarrow A}^{\lambda_{irr}} = \frac{k_{A \rightleftharpoons B}^{\lambda_{irr}}}{\varepsilon_A^{\lambda_{irr}} \times l_{\lambda_{irr}} \times P_{\lambda_{irr}} \times F_{\lambda_{irr}}} - \Phi_{A \rightarrow B}^{\lambda_{irr}} \quad (15)$$

318

319 3.b Fluvo photoreaction

320 The native electronic absorption spectrum of *E-Fluvo* isomer (Fig.1) can be divided into two
 321 main absorption regions, 200–226 nm (Log(ε)= 4.5) and 226–320 nm (Log(ε)= 4.1). This
 322 molecule, thus, absorbs mainly in the UVB region of the spectrum as it is the case for non-
 323 conjugated oximes, with the long wavelength absorption transition having a $\pi \rightarrow \pi^*$
 324 character.²⁷ When exposed to a monochromatic irradiation within that region, the spectrum
 325 of the solution decreases in the regions 200–215 nm and 226–285 nm and increases in the
 326 alternate regions of 215- 226 nm and 285-320 nm (Fig1). The clearly defined isosbestic

327 points (at 215, 226 and 285 nm) and the smooth evolution of the spectra indicate that the
 328 photoreaction is quantitative and proceeds without by-products. Furthermore, *E-Fluvo* and
 329 its photoproduct (*Z-Fluvo*, Scheme 1) share a similar overall spectral shape with a 40 %
 330 maximum variation in absorbance observed at *ca.* 245 nm.

331

332 3.c Determination of the equilibrium constant at an isosbestic irradiation ($K_{A\rightleftharpoons B}^{\lambda_{isos}}$)

333 An *E-Fluvo* aqueous solution was subjected to a 226-nm isosbestic/monochromatic
 334 irradiation and the photoreaction was monitored by HPLC at various time intervals until the
 335 *pss* was reached. The concentration profiles of *E-* and *Z-Fluvo* were readily fitted by Eqs.7
 336 and 8 (Fig.2), and the fitting parameter, the rate-constant $k_{A\rightleftharpoons B}^{\lambda_{isos}}$, as well as the *pss*
 337 concentrations of the reactive species were determined. Subsequently, the forward (Eq.10)
 338 and reverse (Eq.11) quantum yield values as well as the equilibrium constant $K_{A\rightleftharpoons B}^{\lambda_{isos}}$ (Eq.12),
 339 could be calculated (Table 1). At $\lambda_{isos} = 226$ nm, the initial *E*-isomer is found to be more
 340 than twice as photoefficient as its counterpart, as indicated by the value of $K_{A\rightleftharpoons B}^{\lambda_{isos}}$, which
 341 resulted, given that $\epsilon_A^{\lambda_{isos}} = \epsilon_B^{\lambda_{isos}}$, in a higher proportion of the *Z*-isomer in the *pss*
 342 composition, as it is usually observed for *trans-cis* photoisomerization.^{28,29}

343

344 **Table 1:** Overall rate-constant and equilibrium constant for the photodegradation of an
 345 aqueous *Fluvo* solution (1.37×10^{-4} M) exposed to isosbestic monochromatic irradiation at
 346 226 nm, as monitored by *HPLC*.

λ_{isos} /nm	$A_0^{\lambda_{isos}}$	$C_0^{\lambda_{isos}}$ /M	$l_{\lambda_{isos}}$ /cm	$l_{\lambda_{obs}}$ /cm	$C_A(pss)$ /M	$C_B(pss)$ /M	$P_{\lambda_{isos}}$ /einstein.s ⁻¹ .dm ⁻³	$K_{A\rightleftharpoons B}^{\lambda_{isos}}$ /s ⁻¹	$K_{A\rightleftharpoons B}^{\lambda_{isos}}$
226	2.41	1.37×10^{-4}	1	1	4.07×10^{-5}	9.59×10^{-5}	1.88×10^{-6}	3.83×10^{-4}	2.35

347

348 3.d Recovery of the *Z*-isomer's absorption spectrum

349 Based on Eq.13, the spectrum of the medium at *pss* and the spectrum of the *E*-isomer, the
350 electronic absorption spectrum (as absorption coefficients' values) of the *Z*-isomer can be
351 fully reconstructed (Fig. 3).

352

353 3.e Isomers' quantum yields at non-isosbestic irradiation wavelengths

354 Once the absorption spectrum of the *Z*-isomer was known, the two remaining system
355 unknowns ($\Phi_{A \rightarrow B}^{\lambda_{irr}}$ and $\Phi_{B \rightarrow A}^{\lambda_{irr}}$) could then be calculated for any irradiation wavelength using
356 the quantum yield expressions given by Eqs.14 and 15.

357 Seven monochromatic irradiations ($\lambda_{irr} = 290, 285, 280, 270, 260, 245,$ and 226 nm)
358 that span the isomers' absorption spectra, were selected in this study. The kinetic traces were
359 recorded at a unique observation wavelength $\lambda_{obs} = 245$ nm, that corresponds to the most
360 extensive variation of the absorbance (Figs. 1 and 3). In general, a smooth decrease in
361 absorption over irradiation time was observed eventually reaching a plateau region (Fig. 4),
362 as suggested by HPLC measurements. This represents a typical behaviour of AB(2 Φ)
363 systems, which in turn corroborates the mechanism of *Fluvo* photodegradation (Scheme 1).
364 This is also confirmed by the good fitting of the kinetic traces with the model equation, Eq.2,
365 for all non-isosbestic irradiations. Therefore, *Fluvo* photoconversion obeys Φ -order kinetics.

366 The kinetic parameters determined for *Fluvo* photodegradation (Table 2), indicate that
367 the overall rate-constant of photoreaction increases with increasing irradiation wavelength
368 (Table 2). However, as has been comprehensively discussed in previous studies,¹⁰⁻¹² $k_{Fluvo}^{\lambda_{irr}}$
369 dependence on a number of experimental parameters (Eq.3), such as initial concentration and

370 irradiation intensity, reduces its ability to inform about the intrinsic photoreactivity of the
 371 molecule. Therefore, it is mandatory to define, in subsequent steps, the absolute values of the
 372 photoreaction quantum yields at the selected wavelengths.

373 The recommended hypothesis for this type of studies is that the quantum yields of drugs
 374 should *a priori* be supposed wavelength dependent and then test the hypothesis experimentally.

375

376 **Table 2:** Quantum yields, overall rate–constant, absorption coefficient and initial velocity values
 377 for *Fluvo* photodegradation reactions under various monochromatic irradiations, as determined by
 378 the Φ –order kinetics.

λ_{irr}	$A_{Fluvo}^{\lambda_{irr}/245}(0)$	$P_{\lambda_{irr}}$	$A^{\lambda_{irr}}(pss)$	$k_{A \rightleftharpoons B}^{\lambda_{irr}}$	$v_0^{\lambda_{irr}/\lambda_{obs}}(mod.)$	$\epsilon_A^{\lambda_{irr}}$	$\epsilon_B^{\lambda_{irr}}$	$F^{\lambda_{irr}}(0)$	$\Phi_{A \rightarrow B}^{\lambda_{irr}}$	$\Phi_{B \rightarrow A}^{\lambda_{irr}}$
/nm		/einstein. s ⁻¹ .dm ⁻³		/s ⁻¹	/s ⁻¹	/M ⁻¹ cm ⁻¹	/M ⁻¹ cm ⁻¹			
226	0.0393	6.09×10^{-7}	0.0420	0.000197	-2.20×10^{-6}	14254	13802	2.086	0.00383 ± 0.00003	0.00157 ± 0.00027
245	0.0399	5.86×10^{-7}	0.0281	0.000268	-3.09×10^{-6}	13478	8273	2.095	0.00612 ± 0.00042	0.0038 ± 0.001331
260	0.0398	4.60×10^{-7}	0.0191	0.000380	-4.56×10^{-6}	10687	4997	2.14	0.0128 ± 0.00064	0.0085 ± 0.00096
270	0.0405	5.21×10^{-7}	0.0109	0.000670	-8.31×10^{-6}	6679	1859	2.19	0.0361 ± 0.00195	0.025 ± 0.0035
280	0.0398	5.51×10^{-7}	0.0031	0.000875	-1.28×10^{-5}	3109	829	2.25	0.0931 ± 0.00275	0.0535 ± 0.0127
285	0.0400	4.70×10^{-7}	0.0031	0.00048	-1.32×10^{-5}	1774	586	2.27	0.2167 ± 0.0059	0.0844 ± 0.0075
290	0.0402	2.56×10^{-7}	0.0028	0.00152	-6.69×10^{-6}	859	596	2.28	0.4349 ± 0.0205	0.0573 ± 0.0184

379

380

381 It is clearly shown from the results of Table 2 that the forward quantum yield ($\Phi_{A \rightarrow B}^{\lambda_{irr}}$)
 382 increases with increasing wavelength and was always higher than the reverse quantum yield
 383 ($\Phi_{B \rightarrow A}^{\lambda_{irr}}$). The most pronounced variation of the quantum yield ratios ($1.4 > \Phi_{A \rightarrow B}^{\lambda_{irr}} / \Phi_{B \rightarrow A}^{\lambda_{irr}} > 7.6$) is
 384 situated in the longest wavelength, 280 to 290 nm, region (ranging between 1.7 and 7.5), whereas,
 385 a much more modest change in its values is observed in the region 245-280 nm

386 $(1.4 > \Phi_{A \rightarrow B}^{\lambda_{irr}} / \Phi_{B \rightarrow A}^{\lambda_{irr}} > 1.7)$. Furthermore, the evolution of the forward quantum yield values with
387 wavelength has a defined sigmoid pattern (Eq.16, Fig.5).

388

$$\Phi_{A \rightarrow B}^{\lambda_{irr}} = \frac{1}{0.07 + 400 \times e^{-(0.13 \times (\lambda_{irr} - 250))}} \quad (\text{Eq. 16})$$

389

390 This advantageously enables the determination of *E-Fluvo* quantum yield at any desired
391 wavelength using the sigmoid equation (Eq.16).

392 The reverse quantum yield, on the other hand, follows a lower pattern with irradiation
393 wavelength (Fig.5), with a 5.4-fold maximum span of variation for the recorded set of values
394 (whereas 11.4 was recorded for the forward quantum yield). A similar behaviour has been
395 observed for Montelukast.¹² The differing magnitude of photo-efficiencies between *E-* and its *Z-*
396 *Fluvo* isomer might suggest a difference in the excited-state associated with each species. The
397 more pronounced difference between the isomers' quantum yields that was recorded in the longest
398 wavelength region indicates that the excited-state of lowest energy is much more efficient for *E-*
399 than for *Z-Fluvo*. This finding might suppose a more important contribution of the $n \rightarrow \pi^*$ excited-
400 state in *Fluvo* phototransformation. In any case, the increase of quantum yields with irradiation
401 wavelengths, observed for a number of drugs studied in our team, does not have at present a
402 full/comprehensive interpretation. Overall, such results may illustrate a case where not only the
403 chemical nature, the geometry of the molecule but also the irradiation conditions impact the drugs
404 photochemical behaviour.

405 The oxime group within *E-Fluvo* is found to be twice as photochemically efficient as
406 the ethene bond in the stilbene-like Montelukast ($\Phi_{A \rightarrow B}^{\lambda_{irr}} = 0.012-0.18$).¹² In both these cases,

407 as well as for nifedipine,¹⁰ the results show a trend of higher forward quantum yield values
408 for lower-energy excited-states.

409 In terms of photostability, the photoreversibility has the advantage of limiting the
410 depletion of the initial active ingredient to the amounts recorded at the *pss*, however, the *pss*
411 concentration (Z/E) ratios for *Fluvo* isomers,
412 $C_B^{\lambda_{irr}}(pss)/C_A^{\lambda_{irr}}(pss) = (\Phi_{A \rightarrow B}^{\lambda_{irr}} \times \epsilon_A^{\lambda_{irr}})/(\Phi_{B \rightarrow A}^{\lambda_{irr}} \times \epsilon_B^{\lambda_{irr}})$, increases with wavelength from
413 2.5 and reaches a value of 11.3 at 290 nm, which indicates a substantial degradation of the
414 initial species (*E-Fluvo*). In the case of *Fluvo*, this represents a significant decrease in dosage
415 as *Z-Fluvo* is biologically inactive,²⁰ but could be a major issue if for other drugs the
416 photoproduct is toxic. These results stress out the usefulness and necessity of a full kinetics
417 elucidation of drug photodegradation. They also confirm that reliable conclusions about the
418 photoreactivity of a compound can only be reached when using monochromatic irradiation
419 coupled to a treatment using the Φ -order kinetics. It is then reasonable to suggest that the
420 ICH recommendations would benefit from introducing an element of photostability
421 assessment of the drugs at low concentration in solution. Such data would not only shed light
422 on the photokinetic behaviour and photodegradation parameters of the drug *in vitro* but also
423 may lay down a platform for an understanding of the behaviour of drugs *in vivo*. Indeed, the
424 distribution of the administered drugs in the skin and eyes of the patients occurs mostly at
425 low concentration within biological fluids and tissues.^{3,4} Many studies have shown that both
426 topical and systemic drugs can cause different conditions including photosensitivity and
427 dermatoses in all-age patients including newborns.³⁰⁻³³ Even though an exact number of the
428 drugs concerned has not yet been made available, it is nonetheless possible that a very high
429 proportion of existing and future organic drugs, assuming a conservative hypothesis, absorb
430 in the UVA–UVB ranges (some in the visible).^{3,4} These types of radiation traverse through

431 the skin with UVA wavelengths penetrating deep into the dermis.^{3,4,20} Hence, most of drugs
432 can reach the excited-state from which they potentially can subsequently photoreact both in
433 *vitro* and in *vivo*. It has been shown that despite that the absorption spectrum of *Fluvo* ends
434 *ca.* 290 nm (Fig.3), exposing the solution of this drug to UVA-Visible light (simulating day
435 light) also caused its degradation.²¹ As for most drugs, the variability/progress of the
436 photodegradation depends also on the intensity of the light and/or the duration of the
437 exposure. In this context, the FDA, EMEA and ICH have issued guidelines on the evaluation
438 of the photosafety of all new systemic and topical pharmaceuticals capable of absorbing
439 within the UVB, UVA or visible regions with absorption coefficients above $1000 \text{ M}^{-1} \cdot \text{cm}^{-1}$ as
440 well as existing drugs when unaddressed photosafety concerns arise.³⁴⁻³⁶ The regulatory
441 authorities and pharmaceutical industries increasingly recognise photo-induced
442 pharmaceutical and cosmetic drugs' reactions.^{3,4,37} In addition, the advent of an ever wide
443 spreading phototherapy treatments (including home phototherapy),^{38,39} calls for clearer and
444 tighter recommendations for photosafety testing. In this context, testing low concentrated
445 solutions of drugs *in vitro* may arguably benefit the evaluation of the potential and extent of
446 photodegradation that might be undergone by the drug in similar situations *in vivo*. The low
447 concentration studies are also important because the equations of the Φ -order kinetics (Eq.3)
448 show that the rate of photodegradation of drugs increases with decreasing concentration.¹⁰
449 Such low drug concentrations would mimic *in vivo* conditions as for the latter a maximum
450 substrate concentration was set at $100 \mu\text{g/ml}$, in addition to a recommendation to perform
451 several dilutions during the testing procedure.³⁶ This is justified by the fact that most drugs
452 reach the circulation, body tissues and eyes in significantly smaller amounts to the original
453 given dose. Furthermore, the ICH currently recommends an irradiance dose of approximately
454 5 J/cm^2 UVA doses for the *in vitro* 3T3 Neutral Red Uptake phototoxicity test (3T3 NRU PT)

455 to corroborate natural irradiation conditions comparable to those obtained during prolonged
456 outdoor activities on summer days around noon time, in temperate zones and at sea levels.³⁶

457 Therefore, the conditions of the present study reflect well the situation of drugs in the
458 body as small concentrations (*ca.* 1.3 $\mu\text{g/ml}$) and low radiation power (1-2 J/h/cm^2) are
459 employed. Such studies might be thought as a relevant initial platform, that provide reliable
460 data and valuable information about the inherent photoreactivity of a molecule in solution, to
461 feed the evaluation of drugs' photosafety and photodegradation *in vivo*.

462

463 **3.f Photostabilisation of Fluvo photodegradation using excipient–dyes**

464 There is an evident lack in the literature of useful methods to quantify photostabilisation of
465 drugs. The Q1b document⁷ does not propose any detailed procedures in this respect including
466 the case of solutions. In this section, the photoprotection of *Fluvo* with excipient dyes was
467 assessed by Φ –order kinetics.

468 For this purpose, the UV–absorbing food additive/excipient–dye *TRZ* was selected as
469 its spectrum overlaps that of *Fluvo*, hence acting as an absorption competitor. Its effect was
470 evaluated on solutions of *TRZ* of various concentrations, which were each irradiated after the
471 addition of the same amount of *Fluvo*. It is worth mentioning that prior to the addition of
472 *Fluvo*, the *TRZ* solution was considered for the blank experiment on the UV/Vis diode array
473 spectrophotometer. In these conditions, the temporal evolution of the absorbance of the
474 medium could be recorded without the spectral interference of the dye (the latter however
475 does absorb part of the excitation light).

476 The resultant kinetic traces ($\lambda_{irr}/\lambda_{obs} = 280/245$) were fitted with Eq.2 (Fig.6) and
477 their respective reactions rate–constants were determined (Table 3). Indeed, Eqs.1–6 apply
478 except that the total absorbance of the medium at the irradiation wavelength in Eq.4 must take

479 into account the presence of the third molecule of the light-absorption competitor, i.e. the
 480 actual photokinetic factor, $F_{\lambda_{irr}}^{E/Z,TRZ}(\infty)$, involves $A_{tot}^{\lambda_{irr}/\lambda_{irr}}(\infty) = A_{E/Z}^{\lambda_{irr}/\lambda_{irr}}(\infty) + A_{TRZ}^{\lambda_{irr}/\lambda_{irr}}$.
 481 The model equation (Eq.2) fitted well all the curves irrespective of the concentration of TRZ
 482 present in solution (though below the limit of its linearity range). Accordingly, the overall
 483 photoreaction rate-constant decreased with increasing TRZ concentration. Up to 75%
 484 photostabilization of *Fluvo* was recorded for the highest TRZ concentration used in this study
 485 (4.68×10^{-5} M, Table 3). This confirms that the presence of the excipient-dye does not alter
 486 the photodegradation pattern and or quantum yields of the photoreactions but only reduces the
 487 rate of photodegradation. As stipulated by Eq.4., the photodegradation rate reduction is solely
 488 related to a reduction in the value of the photokinetic factor ($F_{\lambda_{irr}}^{E/Z,TRZ}$) which itself is due to
 489 an effective increase of the medium absorbance at λ_{irr} ($A_{E/Z}^{\lambda_{irr}/\lambda_{irr}}(\infty) + A_{TRZ}^{\lambda_{irr}/\lambda_{irr}}$).

490

491 **Table 3:** Dye absorbances, overall reaction rate-constants, photokinetic factors, and
 492 percentage reduction in reaction rates of *Fluvo* photodegradation in the presence of various
 493 concentrations of TRZ when irradiated at 280 nm and observed at 245 nm.

	$A_{dye}^{\lambda_{irr}}$ ^a	$F_{\infty}^{\lambda_{irr}}$	$k_{Fluvo}^{\lambda_{irr}}$ /s ⁻¹	$\frac{k_{Fluvo}^{\lambda_{irr}} (A_{dye}^{\lambda_{irr}} = 0)}{k_{Fluvo}^{\lambda_{irr}} (A_{dye}^{\lambda_{irr}} \neq 0)}$	% reduction ^b
<i>Fluvo</i> ^{c,d}	0	2.28	0.00087	1	0
Tatrazine (TRZ)	0.314	1.18	0.00051	1.71	41.4
	0.406	1.01	0.00044	1.98	49.4
	0.483	0.89	0.00037	2.32	56.9
	0.933	0.51	0.00022	3.87	74.1

494 ^a: Absorbance of the dye measured at the irradiation wavelength of 280 nm for concentrations
 495 given in Fig.6.

496 ^b: The constant concentration of *Fluvo* was 2.95×10^{-6} M.

497 ^c: The radiant power value for the experiments was $P_{390} = 5.06 \times 10^{-6} - 5.18 \times 10^{-6}$
 498 einstein.dm⁻³.s⁻¹.

499 ^d: the optical path lengths: $l_{\lambda_{irr}} = 2$ cm; $l_{\lambda_{obs}} = 1$ cm

500

501 Furthermore, as predicted by Eq.3, a good linear relationship was found between $k_{A \rightarrow B}^{\lambda_{irr}}$
502 and $F_{\lambda_{irr}}^{E/Z,TRZ}$ (with intercept close to zero and a correlation coefficient close to unity) (Fig. 7).

503 A similar phenomenon should also be expected to occur for an increase of the initial
504 concentration of the mother compound (Eq.3), and hence, the rate of the reaction is
505 concentration-dependent. This confirms that zero- and first-order reaction treatments and
506 interpretation of photodegradation kinetics are neither suitable nor reliable approaches.

507 The present Φ -order kinetics equations offer however an easy and useful tool to
508 evaluate photostabilisation of drugs in solution.

509

510

511 3.g Fluvo-Actinometer

512 An additional interesting and useful aspect offered by the equations of Φ -order kinetics is the
513 development of new actinometers. This may represent an important concept because no
514 standard procedures have yet been established for the evaluation of drugs potential for
515 actinometry and/or the proposal of new actinometers.^{5,6,40,41} Besides, the ICH adopted quinine
516 hydrochloride actinometer holds a number of drawbacks that raised many of questions and
517 doubts about its reliability.^{5,6,10,42-44}

518 The assessment of *Fluvo* potential for actinometry is set out by preparing solutions of
519 approximately the same concentration and exposing each one to a monochromatic light of
520 given radiant power values selected from a set for each irradiation wavelength (260, 270, 280,
521 285 and 290 nm). The kinetic traces obtained at the observation wavelength of 245 nm were
522 then well fitted to the model Eq. 2 (Fig.8). A linear correlation was observed between the

523 values of $k_{A\rightleftharpoons B}^{\lambda_{irr}}$ and $P_{\lambda_{irr}}$ for each set of irradiation experiments (Table 4) as predicted by

524 Eq.2. Our experimental $\beta_{\lambda_{irr}}$ and $\delta_{\lambda_{irr}}$ values matched well those calculated from Eqs.3 and 6.

525

526

527 **Table 4:** Correlation equations for the variation of the overall rate-constants ($k_{NIS}^{\lambda_{irr}}$) and
 528 initial reaction velocities ($v_0^{\lambda_{irr}/\lambda_{obs}}$) with radiant power ($P_{\lambda_{irr}}$), of *Fluvo* (2.95×10^{-6} M)
 529 photodegradation in water ($l_{\lambda_{irr}} = 2$ cm; $l_{\lambda_{obs}} = 1$ cm) together with the corresponding $\beta_{\lambda_{irr}}$
 530 and $\delta_{\lambda_{irr}}$ factors, $F_{\lambda_{irr}}(0)$, $F_{\lambda_{irr}}(pss)$ and the span of radiant power employed for various
 531 monochromatic irradiations.

Irradiation wavelength λ_{irr} / nm	Equation of the line ^a	Correlation coefficient, r^2	$F_{\lambda_{irr}}(0)$	$F_{\lambda_{irr}}(pss)$	$P_{\lambda_{irr}} \times 10^7$ /einst.s ⁻¹ .dm ⁻³
$k_{Fluvo}^{\lambda_{irr}} = \beta_{\lambda_{irr}} \times P_{\lambda_{irr}} + \text{intercept}$					
260	$818.4 \times P_{260} + 3 \times 10^{-7}$	0.99	2.136	2.199	2.93 – 4.60
270	$1249 \times P_{270} + 3 \times 10^{-5}$	0.96	2.194	2.244	2.50 – 5.21
280	$1584 \times P_{280} - 1 \times 10^{-6}$	0.99	2.249	2.277	2.70 – 5.51
285	$1998 \times P_{285} + 2 \times 10^{-5}$	0.98	2.273	2.287	2.63 – 4.81
290	$2077 \times P_{290} + 5 \times 10^{-5}$	0.99	2.284	2.291	2.56 – 4.42
$v_0^{\lambda_{irr}/\lambda_{obs}} = \delta_{\lambda_{irr}} \times P_{\lambda_{irr}} + \text{intercept}$					
260	$-10.58 \times P_{260} + 4.8 \times 10^{-7}$	0.93	2.136	2.199	2.93 – 4.60
270	$-14.57 \times P_{270} - 8.9 \times 10^{-7}$	0.98	2.194	2.244	2.50 – 5.21
280	$-25.16 \times P_{280} + 1.3 \times 10^{-6}$	0.99	2.249	2.277	2.70 – 5.51
285	$-28.11 \times P_{285} + 1.8 \times 10^{-7}$	0.99	2.273	2.287	2.63 – 4.81
290	$-31.08 \times P_{290} + 1 \times 10^{-6}$	0.99	2.284	2.291	2.56 – 4.42

532 ^a $k_{Fluvo}^{\lambda_{irr}}$, $v_0^{\lambda_{irr}/\lambda_{obs}}$ and intercepts expressed in s⁻¹; $\beta_{\lambda_{irr}}$ and $\delta_{\lambda_{irr}}$ in einst⁻¹.dm³.

533

534 The gradients of the lines (of $k_{A\rightleftharpoons B}^{\lambda_{irr}}$ vs. $P_{\lambda_{irr}}$), the *beta* factors ($\beta_{\lambda_{irr}}$), represent

535 constant coefficients that are independent of the light intensity for each irradiation

536 wavelength. Additionally, a linear correlation also exists between $v_{0(mod.)}^{\lambda_{irr}/\lambda_{obs}}$ and $P_{\lambda_{irr}}$ with
 537 gradients specific to each irradiation wavelength defined as the $\delta_{\lambda_{irr}}$ factors (Table 4) as
 538 derived from the initial velocity Eq.6. The linear relationships found here confirm the
 539 usefulness of *Fluvo* for actinometry.

540 Plotting the kinetic parameters $\beta_{\lambda_{irr}}$ and $\delta_{\lambda_{irr}}$ against irradiation wavelength, yield
 541 linear correlations, within the 260–290 nm irradiation range, as given by (Fig.9).

542 The procedure for *Fluvo*–actinometry is set out on two simple strategies for the
 543 determination of the radiant power of an unknown source of light ($P_{\lambda_{irr}}^{unk.}$) for the range 260–
 544 290 nm. Firstly, (a)– a fresh solution of *Z-Fluvo* (3×10^{-6} M in water) is subjected to a
 545 monochromatic irradiation (λ_{irr}) beam from the unknown source. (b)– The experimental
 546 kinetic trace hence obtained is fitted to Eq.2 and its $k_{A\rightleftharpoons B}^{\lambda_{irr}}$ value determined; and/or the
 547 $v_{0(mod.)}^{\lambda_{irr}/\lambda_{obs}}$ of the reaction is derived from the trace (Eq.5). In a third step, (c)– the
 548 corresponding values for the $\beta_{\lambda_{irr}}$ and/or $\delta_{\lambda_{irr}}$ factors are worked out from the corresponding
 549 relationships at λ_{irr} as given by the equations laid out in Fig.9. Finally, (d)– the unknown
 550 radiant power of the source is determined from one of the following equations (Eqs.17).

551

$$P_{\lambda_{irr}}^{unk.} = \frac{k_{A\rightleftharpoons B}^{\lambda_{irr}}}{\beta_{\lambda_{irr}}} = \frac{v_{0}^{\lambda_{irr}/\lambda_{obs}}}{\delta_{\lambda_{irr}}} \quad (17a, b)$$

552

553 In order to facilitate even more the actinometric method, the $v_{0,Clid.}^{\lambda_{irr}/\lambda_{obs}}$ values
 554 calculated using Eq.6 were compared to those ($v_{0,Exp.}^{\lambda_{irr}/\lambda_{obs}}$) obtained as the gradient of the

555 linear fit of the data corresponding to the early stages of the reaction (Fig.10). A very good
556 agreement has been found, indicating that the initial velocity values can be worked out from
557 the data corresponding to the first 5 to 10 min of *Fluvo* irradiation. This finding makes the
558 development of AB(2Φ) actinometers a less time-consuming process, which would be
559 decisive for very slow reactions.

560 Nevertheless, if the concentration or path-lengths used in the unknown light source
561 experiment differ from the ones employed in this study (i.e. 2.95×10^{-6} M and $l_{\lambda_{irr}} = 2$ cm,
562 respectively), then the $\beta_{\lambda_{irr}}$ must first be adjusted before being substituted in Eq.17a. This can
563 be achieved by dividing the $\beta_{\lambda_{irr}}$ value obtained in step (c) of the procedure above by
564 $2 \times F_{\lambda_{irr}}(pss)$ (the latter corresponding to our experiment) and then multiplying it by the
565 value of the new path-length and the photokinetic factor corresponding to the path-length and
566 concentration used in the unknown light source experiment. Similarly, a correction is also
567 needed for $v_0^{\lambda_{irr}/\lambda_{obs}}$ if different path-lengths and/or initial concentration were used. This can
568 be achieved by dividing $v_0^{\lambda_{irr}/\lambda_{obs}}$ by $2 \times F_{\lambda_{irr}}(0)$ and then multiplying it by the values of the
569 new path-length and initial photokinetic factor used.

570 As well as facilitating actinometry studies, the $\beta_{\lambda_{irr}}$ can also serve to inform about a
571 photoreaction rate much more reliably than the overall rate-constant or the quantum yields.
572 Unlike $k_{A \rightleftharpoons B}^{\lambda_{irr}}$ and $\Phi^{\lambda_{irr}}$, $\beta_{\lambda_{irr}}$ offers the possibility of comparing the rates of photoreactions
573 within the same or different experimental settings employing the same initial concentrations.
574 This is because $\beta_{\lambda_{irr}}$ takes into account all photoreaction attributes and experimental
575 parameters at the exception of the radiant power (which is hardly replicable – between
576 experiments). This parameter is, therefore, an ideal tool for comparing the photoreaction rates
577 between different experiments and we propose to label it as the “*pseudo-rate-constant*”.

578 (Similarly, $\delta_{\lambda_{irr}}$ could be considered as a *pseudo-initial velocity* varying only with the terms
579 given in Eq.6 but not with radiant power.) For instance, the wavelength causative range for
580 *Fluvo* photodegradation is clearly situated above $\lambda_{irr} = 280$ nm, with $\beta_{\lambda_{irr}}^{Fluvo} > 1500 \text{ einst}^{-1} \cdot \text{dm}^3$.
581 However, if the wavelength range was overlooked, the photodegradation of *Fluvo* is 10
582 to 20 times slower than that of Montelukast with $1.7 \times 10^4 > \beta_{\lambda_{irr}}^{Monte} > 2.8 \times 10^4$ (despite
583 $\Phi_{A \rightarrow B, Fluvo}^{\lambda_{irr}} > \Phi_{A \rightarrow B, Monte}^{\lambda_{irr}}$).¹² Therefore, this parameter opens new perspectives in comparing
584 photoreactions' rates, which have long been awaited, since it is well documented that the
585 (0th-, 1st-, or 2nd-order) overall rate-constant (k) cannot be used comparatively between
586 different experimental settings using the same or different photoreactive species.⁵ The
587 quantum yield, on the other hand, informs specifically on the inherent efficiency of a
588 molecule to photoreact in a particular solvent under a given irradiation wavelength, which
589 would be proportional to the reaction rate if and only if the reactive species is the only
590 compound absorbing the excitation light (Eq.3).^{8,10} However, the quantum yield value does
591 not give a full picture on the photoreaction rate if there are more than one species absorbing
592 irradiation in the medium and/or many photochemical steps are involved in the
593 phototransformation mechanism.

594

595 **4. Conclusion**

596 The above study emphasises the new perspectives offered by the Φ -order kinetic model for
597 photoreversible systems in general. For the particular case of drugs, it sets out a framework
598 for targeted, accurate and complete kinetic studies. Φ -order kinetic then represents a more
599 efficient tool for the assessment and quantification of both photosatbility and
600 photostabilisation of drugs than the classical treatment based on 0th-, 1st- and 2nd-order
601 kinetics. It can serve the development of new technological AB(2 Φ) devices in
602 photomedicine, targeted drug delivery and photo-responsive drug nano-carrier systems.⁴⁵⁻⁴⁸
603 The data provided by such studies may also be of importance for photosafety studies and
604 might be recommended prior to conducting the evermore required *in vivo* safety studies.

605 Using *Fluvo* as an example of photoreversible reaction systems, the model (i)- fitted
606 its full kinetic traces; (ii)- allowed the determination of the overall-rate constant; (iii)-
607 offered the pseudo-rate-constant beta factors as a new and reliable kinetic parameter truly
608 reflective of intra- and inter-experiments' rate of photoreactions; (iv)- allowed the
609 quantification of effects of photostabilising additives; and (v)- presented *Fluvo* as an accurate
610 and reliable actinometer for the 260-290 nm irradiation range.

611

612

613

614

615

616

617 REFERENCES

- 618 1. Koheler, J.M. In Drug-Induced Diseases: Prevention, detection and management
619 (Eds: J.E. Tisdale, D.A. Miller), Hearthsides Publishing. Bethesda, pp. 117-134, 2010.
- 620 2. Bjertness, E. Solar Radiation and Human Health. The Norwegian Academy of
621 Science and Letters, Oslo, pp:102-113, 2008.
- 622 3. Ferguson, J. Investigation of drug-induced photosensitivity in man. *Toxicology*. **226**,
623 25-26, 2006.
- 624 4. Ferguson, J. In *Photodermatology* (Eds: J. Ferguson, J.S. Dover). Photodermatology.
625 Manon Publishing Ltd. London, 2006.
- 626 5. Piechocki, J.T. and K. Thoma, Pharmaceutical Photostability and Photostabilisation
627 Technology. Informa Healthcare, London, 2010.
- 628 6. Tonnesen, H.H. Photostability of Drugs and Drug Formulations (second Edition).
629 CRC Press: London, 2004.
- 630 7. ICH, Guidance for industry Q1B photostability testing of new drug substances and
631 products, *Fed. Regist.* **62**, 27115-27112, 1996.
- 632 8. Maafi, M. and R.G. Brown, The kinetic model for AB(1 Φ) systems: A closed-form
633 integration of the differential equation with a variable photokinetic factor. *J.*
634 *Photochem. Photobiol. A: Chem.*, **187**, 319-324, 2007.
- 635 9. Maafi, M. and R. Brown, Kinetic analysis and kinetic elucidation options for
636 AB(1k,2 Φ) systems. New Spectrokinetic methods for photochromes. *Photochem.*
637 *Photobiol. Sci.*, **7**, 1360 – 1372, 2008.
- 638 10. Maafi, W. and M. Maafi, Modelling Nifedipine Photodegradation, Photostability and
639 Actinometric Properties. *Int. J. Pharm.*, **456**, 153–164, 2013.
- 640 11. Maafi, M. and W. Maafi, Φ -order kinetics of photoreversible drug reactions. *Int. J.*
641 *Pharm.*, **471**, 536–543, 2014.
- 642 12. Maafi, M. and W. Maafi, Montelukast photodegradation: Elucidation of Φ -order
643 kinetics, determination of quantum yields and application to actinometry. *Int. J.*
644 *Pharm.*, **471**, 544–552, 2014.

- 645 13. Fukui, N., Y. Suzuki, T. Sugai, J. Watanabe, S. Ono, N. Tsuneyama and T. Someya,
646 Promoter variation in the catechol-*O*-methyltransferase gene is associated with
647 remission of symptoms during fluvoxamine treatment for major depression. *Psych.*
648 *Res.*, **218**, 353–355, 2014.
- 649 14. Figgitt, D.P. and K.J. McClellan, Fluvoxamine: An updated review of its use in the
650 management of adults with anxiety disorders. *Drugs.* **60**, 925-954, 2000.
- 651 15. Benfield, P. and A. Ward, Fluvoxamine: a review of its pharmacodynamics and
652 pharmacokinetic properties, and therapeutic efficacy in depression illness. *Drugs.* **32**,
653 313–334, 1986.
- 654 16. Honda, M., K. Uchida, M. Tanabe and H. Ono, Fluvoxamine, a selective serotonin
655 reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-
656 HT2A/2C receptors. *Neuropharmacology.* **51**, 866-872, 2006.
- 657 17. Velasco, A., C. Alamo, J. Heras and A. Carvajal, Effects of fluoxetine hydrochloride
658 and fluvoxamine maleate on different preparations of isolated guinea-pig and rat
659 organ-tissues. *Gen. Pharmacol.* **28**, 509-512, 1997.
- 660 18. Muck-Seler, D., N. Pivac and M. Diksic, Acute treatment with fluvoxamine elevates
661 rat brain serotonin synthesis in some terminal regions: an autoradiographic study.
662 *Nucl. Med. Biol.*, **39**, 1053-1057, 2012.
- 663 19. Panahia, H.A., Y.T.E. Monirib and E. Keshmirizadeh, Synthesis and characterization
664 of poly[*N*-isopropylacrylamide-*co*-1-(*N,N*-bis-carboxymethyl)amino-3-allylglycerol]
665 grafted to magnetic nano-particles for the extraction and determination of
666 fluvoxamine in biological and pharmaceutical samples. *J. Chromatogr. A.*, **1345**, 37–
667 42, 2014.
- 668 20. Miolo, G., S. Caffieri, L. Levorato, M. Imbesi, P. Giusti, T. Uz, R. Manev and H.
669 Manev, Photoisomerization of fluvoxamine generates an isomer that has reduced
670 activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation.
671 *Eur. J. Pharmacol.*, **450**, 223– 229, 2002.
- 672 21. Kwon, J.W. and K.L. Armbrust, Photo-isomerization of fluvoxamine in aqueous
673 solutions. *J. Pharm. Biomed. Anal.*, **37**, 643–648, 2005.

- 674 22. Iijima, K., M. Suzuki, T. Sakaizumi and O. Ohashi, Molecular structure of gaseous
675 acetoxime determined by electron diffraction. *J. Mol. Struct.*, **413-414**, 327-331,
676 1997.
- 677 23. Black, M. and K. Armbrust, 2007. Final Report: The Environmental Occurrence,
678 Fate, and Ecotoxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Aquatic
679 Environments. Available at:
680 [http://cfpub.epa.gov/ncer_abstracts/index.cfm/fuseaction/display.abstractDetail](http://cfpub.epa.gov/ncer_abstracts/index.cfm/fuseaction/display.abstractDetail/abstract/1755/report/F)
681 [/abstract/1755/report/F](http://cfpub.epa.gov/ncer_abstracts/index.cfm/fuseaction/display.abstractDetail/abstract/1755/report/F). Accessed on 3 January 2015.
- 682 24. Maafi, M. The potential of AB(1 Φ) systems for direct actinometry. Diarylethenes as
683 successful actinometers for the visible range. *Phys. Chem. Chem. Phys.*, **12**, 13248–
684 13254, 2010.
- 685 25. Maafi, M. and R. Brown, General analytical solutions for the kinetics of AB(k, Φ) and
686 ABC(k, Φ) systems. *Int. J. Chem. Kinet.*, **37**, 162 – 174, 2005.
- 687 26. Maafi, M. and R. Brown, Analysis of diarylnaphthopyran kinetics. Degeneracy of the
688 kinetic solution. *Int. J. Chem. Kinet.*, **37**, 717 – 727, 2005.
- 689 27. Gilbert, A., J. Bagott, Essentials of molecular photochemistry. Blackwell Science.
690 Oxford, 1991.
- 691 28. Neckers, D.C., D.H. Volman and G. Von Bunau, Advances in photochemistry, vol.
692 19. John Wiley & Sons, New York, 1995.
- 693 29. Singh, J. Photochemistry and pericyclic reactions. New Age International, New Delhi,
694 2005.
- 695 30. Kutlubay, Z., A. Sevim, B. Engin and Y. Tuzun, Photodermatoses, including
696 phototoxic and photoallergic reactions (internal and external). *Clin. Dermatol.*, **32**,
697 73–79, 2004.
- 698 31. Arnold, A., C. Pedroza and E. Tyson, Phototherapy in ELBW newborns: Does it
699 work? Is it safe? The evidence from randomized clinical trials. *Semin. Perinatol.*, **38**,
700 452–464, 2014.
- 701 32. Feldmeyer, L., G. Shojaati, K.S. Spanaus, A. Navarini, B. Theler, D. Donghi, M.
702 Urosevic-Maiwald, M. Glatz, L. Imhof, M.J. Barysch, R. Dummer, M. Roos, L.E.

- 703 French, C. Surber and G.F.L. Hofbauer, Phototherapy with UVB narrowband,
704 UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. *J.*
705 *Am. Acad. Dermatol.*, **69**, 530–536, 2013.
- 706 33. Drucker, A.M. and A.M.C.F. Rosen, Drug-induced photosensitivity: culprit drugs,
707 management and prevention. *Drug Saf.* **34**, 821–837, 2011.
- 708 34. ICH(S10), 2013. ICH Harmonised Tripartite Guideline Photosafety Evaluation of
709 Pharmaceuticals S10. Available at:
710 [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S10/
711 S10_Step_4.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S10/S10_Step_4.pdf) . Accessed on 3 January 2015.
- 712 35. FDA Food and Drug Administration Center for Drug Evaluation and Research
713 (CDER), 2003. Guidance for Industry: Photosafety Testing. Available at:
714 <http://www.fda.gov/cder/guidance/index.htm>. Accessed on 3 January 2015.
- 715 36. The European Agency for the Evaluation of Medicinal Products (EMA), 2002.
716 Committee for Proprietary Medicinal Products (CPMP). Note for guidance on
717 photosafety testing. CPMP/SWP/398/01. Available at: <http://www.emea.eu.int/>.
718 Accessed on 3 January 2015.
- 719 37. Krul, C., W. Maas, R. Van Meeuwen, N. De Vogel and M.J. Steenwinkel, In vivo
720 photogenotoxicity testing, bridging the gap between in vitro photogenotoxicity and
721 photocarcinogenicity testing. *Toxicology*. **226**, 1-25, 2006.
- 722 38. Cameron, H., S. Yule, R.S. Dawe, H. Ibbotson, H. Moseley and J. Ferguson, Review
723 of an established UK home phototherapy service 1998-2011: improving access to a
724 cost-effective treatment for chronic skin disease. *Public Health*. **128**, 317–324, 2014.
- 725 39. Gambichler, T., S. Terras and A. Kreuter, Treatment regimens, protocols, dosage, and
726 indications for UVA1 phototherapy: facts and controversies. *Clin. Dermat.*, **31**, 438-
727 454, 2013.
- 728 40. Kuhn, H.J., S.E. Braslavsky and R. Schmidt, Chemical actinometry (IUPAC
729 Technical Report). *Pure appl. Chem.*, **76**, 2105-2146, 2004.
- 730 41. Montali, M., A. Credi, L. Prodi and M.T. Gandolfi, Handbook of photochemistry (3rd
731 Ed.). CRC Press – Taylor & Francis, Boca Raton-London-New York, 2006.

- 732 42. Baertschi, S.W. Commentary on the quinine actinometry system described in the ICH
733 draft guideline on photostability testing of new drug substances and products. *Drug*
734 *Stab.*, **1**, 193–195, 1997.
- 735 43. Baertschi, S.W., K.M. Alsante and H.H. Tonnesen, A critical assessment of the ICH
736 guideline on photostability testing of new drug substances and products (Q1B):
737 recommendation for revision. *J. Pharm. Sci.*, **99**, 2934–2940, 2010.
- 738 44. De Azevedo Filho, C.A., D. De Filgueiras Gomes, J.P. De Melo Guedes, R. M. F.
739 Batista and B.S. Santos, Considerations on the quinine actinometry calibration method
740 used in photostability testing of pharmaceuticals. *J. Pharm. Biomed. Anal.* **54**, 886–
741 888, 2011.
- 742 45. Wohl, B.M. and J.F.J. Engebensen, Responsive layer-by-layer materials for drug
743 delivery. *J. Control.Release.* **158**, 2-14, 2012.
- 744 46. Tomatsu, I., K. Peng and A. Kros, Photoresponsive hydrogels for biomedical
745 applications. *Adv. Drug Del. Rev.* **63**, 1257-1266, 2011.
- 746 47. Fomina, N., J. Sankaranarayanan and A. Almutairi, Photochemical mechanisms of
747 light-triggered release from nanocarriers. *Adv. Drug Del. Rev.* **64**, 1005-1020, 2012.
- 748 48. Feliciano, M., D. Vylta, K.A. Medeiros and J.J. Chambers, The GABA_A receptor as a
749 target for photochromic molecules. *Bioorg. Med. Chem.*, **18**, 7731-7738, 2010.
- 750

Figures




Fig. 1. Evolution of the electronic absorption spectra of 4.01×10^{-6} M *Fluvo* in water subjected to steady state irradiation with a 270-nm monochromatic beam (total irradiation time 26 min at a radiant power of $P_{270} = 7.37 \times 10^{-7}$ einstein. s^{-1} . dm^{-3}). The arrows indicate the direction of the absorbance evolution during the photoreaction and the vertical lines cross the spectra at the isosbestic points (215, 226, 285 nm).




Fig. 2: Change in aqueous *E*-Fluvo solution (1.37×10^{-4} M) and its *Z*-isomer photoproduct concentrations over 5 hours upon exposure to an isosbestic monochromatic irradiation of 226 nm ($P_{226} = 1.88 \times 10^{-6}$ einstein. s^{-1} . dm^{-3}) as monitored by HPLC.




Fig. 3. Electronic absorption spectra (absorption coefficient units) of *E*- (native) and *Z*-Fluvo (recovered).




Fig. 4. The photokinetic traces of *Fluvo* photodegradation in water (2.95×10^{-6} M) at $\lambda_{irr} = 226, 245, 260, 270, 280, 285$ and 290 nm and observed at $\lambda_{obs} = 245$ nm. The geometric shapes represent the experimental data while the continuous lines represent the model fitted traces using the appropriate model equation.




Fig. 5: Average forward ($\Phi_{A \rightarrow B}^{\lambda_{irr}}$) (diamonds) and reverse ($\Phi_{B \rightarrow A}^{\lambda_{irr}}$) (plain circles) *Fluvo* quantum yields for irradiation wavelengths 226, 245, 260, 270, 280, 285 and 290 nm.




Fig. 6: Effect of increasing *TRZ* concentrations on the photodegradation traces of 2.95×10^{-6} M aqueous *Fluvo* solutions when irradiated at 280 nm and observed at 245 nm.




Fig. 7: Linear relationship between *Fluvo* overall rate-constant of photodegradation in the presence of increasing concentrations of *TRZ* with the corresponding photokinetic factors ($F_{\lambda_{irr}}^{dye}(\infty)$).




Fig. 8. Effect of increasing the irradiation radiant power ($P_{\lambda_{irr}}$) on the kinetic traces of *Fluvo* (2.97×10^{-6} M) when irradiated at 280 nm and observed at 245 nm. The circles represent the experimental data while the lines represent the model fitted traces.




Fig. 9: Linear correlation between $\beta_{\lambda_{irr}}$ and $\delta_{\lambda_{irr}}$ with irradiation wavelength.

$$\beta_{\lambda_{irr}} \text{ and } \delta_{\lambda_{irr}} \text{ in } \text{einst}^{-1} \cdot \text{dm}^3.$$




Fig. 10: Correlation between $v_{0(Cld.)}^{\lambda_{irr}/\lambda_{obs}}$ and $v_{0(Exp.)}^{\lambda_{irr}/\lambda_{obs}}$ for all the sets of *Fluvo* actinometry experiments in Table 4.